ACTG Announces Launch of its First HIV Cure Clinical Trial in Africa
Retrieved on:
Jeudi, juin 13, 2024
Aurum, NIH, Hook effect, HIV Vaccine Trials Network, Immune system, HVTN, Control, Management of HIV/AIDS, Research, Doctor of Philosophy, Rockefeller University, Infection, Weill Cornell Medicine, Viral load, Clinical trial, University of North Carolina, NIAID, Safety, MPH, Bill, University, Prevalence, HPTN, Chairperson, Antibody, UNC, ART, Chair, ACTG, HIV, CD4, Woman, Bangladesh Technical Education Board
Even when taking ART, people living with HIV have latent HIV reservoirs – groups of immune cells that contain HIV but do not produce new copies.
Key Points:
- Even when taking ART, people living with HIV have latent HIV reservoirs – groups of immune cells that contain HIV but do not produce new copies.
- “In order to ensure that the HIV cure approaches we develop are broadly effective and accessible, it is vital that HIV cure research be conducted among the global population of people living with HIV,” said ACTG Chair Judith Currier, M.D., M.Sc., University of California Los Angeles.
- It is open to select ACTG, HVTN, and HPTN clinical research sites in Africa.
- “Ensuring that HIV cure strategies work for diverse populations is key to ACTG’s HIV cure research agenda,” said Marina Caskey, MD, the Rockefeller University and Weill Cornell Medicine, and Vice-Chair of PAUSE.